Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors

October 18th 2022

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

Pembrolizumab Confers Long-Term OS Benefit in Head and Neck Squamous Cell Carcinoma

October 17th 2022

Pembrolizumab, alone and in combination with chemotherapy, maintained an overall survival benefit compared with cetuximab plus chemotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma at 4 years.

Dr. Saba on Disparities of Clinical Trials in Head and Neck Cancer

October 6th 2022

Nabil Saba, MD, FACP, discusses the disparities seen in clinical trials in head and neck cancer.

CUE-101 Gets Fast Tracked for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

October 5th 2022

The FDA has granted a fast track designation to CUE-101 for use as a monotherapy and in combination with pembrolizumab in patients with human papillomavirus recurrent or metastatic head and neck squamous cell carcinoma.

PDS0101 Plus Pembrolizumab Under Further Evaluation in HPV16+ HNSCC

October 4th 2022

The FDA has agreed on key elements of the clinical program to support the biologic license application for the combination of PDS0101 and pembrolizumab for the treatment of unresectable, recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma.

FDA Grants Fast Track Designation to Ficlatuzumab for Relapsed or Recurrent HNSCC

September 23rd 2022

The FDA has granted a fast track designation to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma.

Lenvatinib/Pembrolizumab Combo Proves Safe, Effective for Metastasized Anaplastic and Poorly Differentiated Thyroid Carcinoma

September 13th 2022

The combination of lenvatinib and pembrolizumab was found to induce high response rates, including long-lasting remissions, and have acceptable safety in patients with metastasized anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma.

Pembrolizumab Plus Chemoradiation Shows Only Numerically Improved EFS, OS in Locally Advanced Head and Neck Cancer

September 11th 2022

Pembrolizumab plus chemoradiation failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation alone in patients with locally advanced head and neck squamous cell carcinoma.

Xevinapant Plus Standard Chemoradiotherapy Demonstrates Sustained Benefit in Locally Advanced HNSCC

September 11th 2022

The addition of xevinapant to standard-of-care chemoradiotherapy elicited continued 5-year overall survival and 3-year duration of response benefits in patients with unresected head and neck locally advanced squamous cell carcinoma.

New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders

August 5th 2022

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

INTERLINK-1 Trial Terminated Following Failed Futility Analysis of Monalizumab/Cetuximab in Head and Neck Cancer

August 1st 2022

The phase 3 INTERLINK-1 trial was discontinued after monalizumab plus cetuximab failed to meet a predefined threshold for efficacy compared with cetuximab alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

IRX-2 Immunotherapy Misses EFS End Point in Newly Diagnosed Head and Neck Cancer

July 27th 2022

IRX-2 failed to demonstrate a statistically significant improvement in event-free survival as neoadjuvant therapy compared with standard of care in patients with newly diagnosed, stage II, III, or IVA squamous cell carcinoma of the oral cavity.

Pembrolizumab Plus Chemoradiation Misses EFS End Point in Head and Neck Squamous Cell Carcinoma

July 20th 2022

Pembrolizumab plus concurrent chemoradiation followed by pembrolizumab maintenance did not lead to a statistically significant improvement in event-free survival vs concurrent chemoradiation alone in patients with unresected locally advanced head and neck squamous cell carcinoma.

Cabozantinib Demonstrates Long-Term PFS Benefit in Radioiodine-Refractory Differentiated Thyroid Cancer

July 13th 2022

Cabozantinib monotherapy maintained continued to provide a superior progression-free survival benefit to that achieved with placebo in adults with locally advanced or metastatic differentiated thyroid carcinoma, irrespective of histology, according to updated data from the phase 3 COSMIC-311 trial.

Enoblituzumab Trial Ended Early Due to Safety Concerns in Head and Neck Squamous Cell Carcinoma

July 11th 2022

The phase 2 CP-MGA271-06 trial closed early following an internal review of safety data of enoblituzumab plus retifanlimab or tebotelimab as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

FDA Accepts BLA Resubmission for Toripalimab in Advanced Nasopharyngeal Carcinoma

July 6th 2022

The FDA has accepted for review a biologics license application resubmission for toripalimab both in combination and as monotherapy for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, according to an announcement from drug developer Coherus.

FDA Grants Fast Track Status to PDS0101/Pembrolizumab Combo for Recurrent or Metastatic, HPV16+ Head and Neck Cancer

June 16th 2022

The FDA has granted a fast track designation to PDS0101 for use in combination with pembrolizumab in patients with recurrent or metastatic HPV16-positive head and neck cancer.

Updated RATIONALE-309 Data Support Use of Tislelizumab/Chemo in Frontline Recurrent/Metastatic Nasopharyngeal Cancer

June 9th 2022

Tislelizumab plus chemotherapy continued to improve progression-free survival over chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated data from the RATIONALE-309 trial.

PDS0101 Shows Synergistic Activity With Pembrolizumab in HPV16+ Head and Neck Squamous Cell Carcinoma

June 7th 2022

The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.

Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma

June 7th 2022

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.